hVIVO plc £13.1m contract to develop an influenza B virus challenge model

hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced a £13.1m contract with an existing top five global pharmaceutical client to develop an Influenza B (“Flu B”) human challenge model.

Highlights

·    Key prerequisite phase of manufacturing virus is complete

·    Characterisation trial due to commence in Q4 2023 following completion of manufacturing process

·    Supplementary fee to ensure expedited delivery and guaranteed availability of beds

·    Potential for a future challenge trial pending a successful characterisation study

The contract scope includes the manufacture of an influenza B challenge virus, a characterisation study, and a supplementary fee to ensure sufficient capacity is available to complete the characterisation trial in an expedited manner. The successful manufacturing of the challenge virus is a prerequisite for the characterisation trial revenue to be delivered, and with the Good Manufacturing Practice (GMP) challenge agent manufacture now in its final stages, the Company will be able to commence the characterisation study in Q4 2023.

The characterisation study aims to identify a dose of influenza B that elicits a safe and reproducible infection in healthy volunteers recruited through the FluCamp platform. Subject to the successful completion of the characterisation study and the receipt of relevant regulatory approvals, the Company expects to conduct an influenza B human challenge trial in H1 2024. Revenue from this human challenge model development contract will be recognised throughout 2023 and 2024.

hVIVO is proud to be the exclusive contract research organisation offering this bespoke human challenge model development services with unparalleled knowledge and expertise in this field spanning back as far as the UK Common Cold Unit. Testing medicines against specific virus strains offer numerous benefits to biopharma clients including the certainty of testing efficacy against specific and new strains of virus.

The Centers for Disease Control and Prevention reports that both influenza A and B can have equally severe symptoms,1 although type B is less prevalent. Similar to type A, influenza B is also highly contagious and can cause life-threatening complications in severe cases. Unlike influenza A viruses, which are known to infect a variety of different species and, therefore, have pandemic potential, influenza B viruses typically only infect humans. Influenza B causes seasonal epidemics and gradually evolves to evade the immune system so, like influenza A viruses, the seasonal vaccine component against influenza B virus needs to be updated frequently to maximise protective efficacy.

Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said: “This is the second bespoke human challenge model development contract announced in as many months and continues the trend of large contract wins for hVIVO. This existing top five global pharmaceutical client will support the development of a new influenza B challenge model to potentially test its vaccine candidate, in turn furthering our industry leading position by broadening our library of human challenge models. Importantly, the contract also further diversifies our revenue pipeline across challenge agents and provides further visibility of revenue into 2024.”

Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, said: “hVIVO is the only commercial provider of human challenge trial services that can offer human challenge model development services to ensure that challenge models are available to meet the specific needs of our customers. The creation of a Flu B challenge model will potentially allow this top five global pharmaceutical client’s vaccine candidate to gain quick efficacy data against a type of influenza which is near impossible to achieve via traditional field trials. This unparalleled efficacy data is extremely valuable, as it can open up new markets and strengthen product label claims, significantly increasing the potential value of existing clinical assets.”

1 https://www.healthline.com/health/influenza-b-symptoms

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    hVIVO Careers – Fueling Scientific Research

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Hvivo raises full year sales and earnings guidance

    The Dublin-headquartered pharmaceutical services company said it expects to generate full year sales of £55m and earnings margins of 19 per cent Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, has increased its sales and

    hVIVO plc

    hVIVO reports surge in half year revenues as HCTs rise

    hVIVO, formerly Open Orphan, has today reported a jump in revenues and earnings for the six months to the end of June and said its outlook for the full year was “extremely positive”. It raised its 2023 revenue

    hVIVO plc

    hVIVO plc Upgraded Full Year Revenue and EBITDA Guidance

    hVIVO plc (Euronext & LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2023. Financial highlights ·    First half revenue growth of

    hVIVO plc

    A day in the life of a clinical trial volunteer

    What does a day look like as a clinical trial volunteer? FluCamp is a leading clinical research organization focused on studying and developing treatments for respiratory illnesses. We conduct clinical trials and recruit volunteers to contribute to medical

    hVIVO plc

    Hvivo to move to larger “state-of-the-art” facility in London

    The Dublin-headquartered pharmaceutical services company said the expanded facility would allow it to capitalise on its growing order book Hvivo, the Dublin-listed pharmaceutical services company founded by businessman Cathal Friel, has announced plans to move to a new,

    hVIVO plc

    Biotech hVIVO expanding clinical trial capacity

    The Irish-founded biotech Hvivo is expanding its operations in London to meet growing demand for its human challenge clinical trial services. Clinical-trial specialist biotech hVIVO has announced the planned expansion of its life sciences hub in Canary Wharf,

    hVIVO plc

    Hvivo plans larger London facility to meet demand

    Pharmaceutical services firm Hvivo, formerly Open Orphan, has announced plans to open a larger facility in response to the company’s growing order book. Hvivo focuses on advancing research in infectious and respiratory diseases. The new facility will be

    hVIVO plc

    hVIVO plans for a new consolidated facility in Canary Wharf, London

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its plans for a new consolidated facility at the fast-growing life sciences hub in Canary Wharf, London. The expansion,

    hVIVO plc

    hVIVO to release interim results on Tuesday 12 September 2023

    hVIVO plc (LON:HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its interim results for the six months ended 30 June 2023 on Tuesday 12 September

    hVIVO plc

    How our Drug Development Plan can help you get funding

    An academic spin-off biotech with only a handful of people on board was preparing for their new biological entity for clinical development. For the drug product itself, they needed to a CMC process and conduct necessary nonclinical studies.

    hVIVO plc

    VP of Clinical Operations on hVIVO’s new Facility

    hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services

    hVIVO plc

    Developing an Influenza B Human Challenge Model

    Dr. Andrew Catchpole, Chief Scientific Officer discusses hVIVO’s bespoke human challenge model development services focusing on our most recent Flu B model. He highlights the various stages of this contract & the fundamental steps hVIVO takes to ensure

    No more posts to show